Search results
Results From The WOW.Com Content Network
Calcium channel blockers (CCB), calcium channel antagonists or calcium antagonists [2] are a group of medications that disrupt the movement of calcium (Ca 2+ ) through calcium channels . [ 3 ] Calcium channel blockers are used as antihypertensive drugs , i.e., as medications to decrease blood pressure in patients with hypertension .
Plasma half-life of 2–8 or 4.5–12 hours after single oral dose or multiple oral doses, respectively. ... Calcium channel blockers like verapamil dilate the ...
Calcium channel blockers, including amlodipine, ... Its long half-life and high bioavailability are largely in part of its high pKa (8.6); ...
Nebivolol is a beta blocker used to treat high blood pressure and heart failure. [5] As with other β-blockers, it is generally a less preferred treatment for high blood pressure. [6] It may be used by itself or with other blood pressure medication. [6] It is taken by mouth. [6] Common side effects include dizziness, feeling tired, nausea, and ...
Nifedipine, sold under the brand name Procardia among others, is a calcium channel blocker medication used to manage angina, high blood pressure, Raynaud's phenomenon, and premature labor. [2] It is one of the treatments of choice for Prinzmetal angina. [2] It may be used to treat severe high blood pressure in pregnancy. [2]
Like other dihydropyridine class calcium channel blockers, ... Elimination half-life is 8 to 10 hours, and the drug does not accumulate. Because of the depot effect ...
Clevidipine (INN, [2] trade name Cleviprex) is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. Clevidipine is used IV only and practitioners titrate this drug to lower blood pressure. It has a half-life of approximately one minute.
Isradipine (tradenames DynaCirc, Prescal) is a calcium channel blocker of the dihydropyridine class. It is usually prescribed for the treatment of high blood pressure in order to reduce the risk of stroke and heart attack. It was patented in 1978 and approved for medical use in 1989. [1]